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Abstract 
The Gastroenterology and Molecular cell biology research group examines biological 
mechanisms that are important in the development of gastric cancer. The peptide 
hormone gastrin is known to play a role in organization and maintenance of the 
gastric epithelium, however, its role in carcinogenesis is debated. Gastrin induces the 
expression of the nuclear transcription factor NR4A2. NR4A2 expression has been 
suggested as prognostic factors and potential therapeutic targets for patients with 
different cancer types, including gastric cancer. The biological functions of NR4A2 in 
tumors and the prognostic significance are incomplete and needs to be further studied. 
 
Recent studies indicate that NR4A2 protein-protein interactions as well as its sub-
cellular localization are of vital importance when it comes to the specific cellular 
response. The aim of this study was to characterize interacting partners of NR4A2 in 
cellular model systems. 
 
In the present study, the expression of the CCK2 receptor and gastrin induced NR4A2 
expression in gastric carcinoma cell lines were examined. The MKN45 and HEK293 
cells were used to characterize protein-protein interactions of NR4A2. No interactions 
were observed between NR4A2 and the proteins initially hypothesized to bind to 
NR4A2. However, Mass Spectrometry in combination with immunoprecipitation 
identified several potential binding partners. This thesis provides an overview of 
potential interactions partners of NR4A2 that may be important in gastric cancer and 
can provide candidate proteins for further work.  	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1.0 Introduction  
1.1 Gastric cancer 
Gastric cancer is a major public health issue. It is the second leading cause of cancer-
related death worldwide and the fourth most common cancer type [1]. Overall there 
has been a downward trend of gastric cancer during the past 70 years; both the 
mortality and the incidence have fallen dramatically. However, the decline is 
predominantly caused by the decrease in distal, intestinal type adenocarcinoma, 
whereas the incidence of proximal, diffuse type adenocarcinoma has been increasing 
[2]. Gastric cancer is an aggressive disease with a high mortality rate. In Europe, the 
5-years survival rate is less than 25% in all gastric cancer patients [3]. Recurrence 
after curative-intent resection occur in approximately 40-60% of the patients [4]. 
 
Gastric cancer is a multifactorial disease and results from a combination of 
environmental factors and genetic alteration (figure 1.1). Gastric cancer affects 
mainly older patients that have experienced an extensive period with atrophic 
gastritis. Gastritis is commonly caused by Helicobacter pylori infection and is the 
single most common cause of gastric cancer [5]. H. pylori infection is unlikely to be 
responsible for gastric cancer development by itself, but might provide an 
environment leading to carcinogenesis and may impact other environmental 
exposures and lifestyle. Increased risk of gastric cancer is associated with salty food 
and N-nitroso compounds and low consumption of fresh fruits and vegetables. Use of 
tobacco, obesity, pernicious anemia are also thought to increase the risk of gastric 
cancer [2].  
 
About 90% of gastric cancers are adenocarcinomas, where the cancer develops from 
cells of the innermost lining of the stomach [2]. Two histological types of 
adenocarcinoma are characterized, diffuse and intestinal. These two types show 
different epidemiological and pathological features. The diffuse type is more frequent 
in young patients, can be multifocal and hereditary. It generally evolves after chronic 
inflammation without passing through the intermediate steps of atropic gastritis or 
intestinal metaplasia (figure 1.1) [5]. Intestinal type occur more commonly in older 
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patients, and are often related to environmental factors such as H. pylori infection, 
diet and lifestyle [6]. The development follows multifocal atropic gastritis, 
accompanied by intestinal metaplasia and leads to cancer through dysplasia (figure 
1.1) [5]. 
 
 
Figure 1.1. Schematic representation of the development of gastric cancer. Development of 
intestinal type of gastric cancer follows a characteristic pathological pathway, comprising progression 
from atrophic gastritis, via metaplastic to dysplasia and malignancy. Diffuse type of gastric cancer 
develops from normal gastric epithelium, generally after chronic inflammation (Modified from 
Burkitt et al. [7]). 
 
During gastric carcinogenesis an accumulation of genetic abnormalities occurs and 
some variations have been reported to increase the risk of developing gastric cancer. 
Oncogenic activation and tumor-suppressor gene inactivation plays crucial roles in 
the process of tumorigenesis and cellular immortalization. Other important factors are 
inactivation of DNA repair genes and cell adhesion proteins, overexpression of 
growth receptors and growth factors [6, 8]. 
1.2 Gastrin 
The polypeptide hormone gastrin is important in regulating gastric acid secretion [9]. 
Gastrin has been shown to have an important role in maintaining functional integrity 
of the gastric epithelium and is also known to stimulate gastric mucosal growth [10]. 
The gastrin gene (GAST) encodes a 101 amino acid polypeptide, preprogastrin. After 
synthesis of preprogastrin, the gene products are prone to different posttranslational 
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modifications that result in different biologically active peptides. Gastrin- 17 is the 
predominated form secreted in the human stomach [7]. In addition, gastrin is also 
expressed in the colon, fatal islets in pancreas, pituitary and spermatozoa but in lower 
levels [11]. In the mature form, gastrin interacts with the G protein-coupled receptor 
cholecystokinin 2 (CCK2) receptor [12]. The CCK2 receptors are located on several 
cell types in the central nervous system and peripheral organs including the stomach. 
In the gastric epithelium, it is primarily the parietal cells and enterochromaffin-like 
(ECL) cells that possess the CCK2 receptor [10].  
1.2.1 Acid secretion 
The main function of gastrin is to regulate gastric acid (HCl) secretion in the gastric 
mucosa to maintain the appropriate acidic pH for the digestive enzymes [13]. Gastrin 
is synthesized and secreted by G cells located in the gastric antrum of the stomach 
(figure 1.2) [12]. The G cells respond to a number of luminal stimuli including amino 
acids and dietary amines [7]. Subsequently, gastrin is transported to the oxyntic 
mucosa in an endocrine manner and interacts with gastrin receptors on ECL cells and 
potentiates the release of histamine. An increase in histamine concentration induces 
gastric acid secretion by parietal cells [13]. Gastrin secretion is tightly regulated by 
gastrin-releasing peptide (GRP) and somatostatin as a positive and a negative 
regulator, respectively, to facilitate the release of gastric acid from parietal cells [13]. 
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Figure 1.2. The role of gastrin in acid secretion regulation. The upper part of the stomach consisting 
of cardia, fundus and corpus and is involved in acid secretion. The lower part, antrum and pylorus, are 
the main site for gastrin synthesis in the G-cells. Gastrin is secreted and enters the circulation and act 
on the CCK2 receptors at the ECL cells. Upon gastrin stimulation the ECL cells release histamine that 
act on parietal cells and stimulating them to secret gastric acid. Gastrin secretion is regulated by the 
two proteins somatostatin and gastrin-releasing peptide (Modified from Watson et al. [13] and Burkitt 
et al. [7]). 
 
1.2.2 Homeostasis of gastric mucosa 
The gastric epithelium is folded into tubular branched gastric glands that reach deep 
into the muscularis mucosa (figure 1.2). Pluripotent stem cells are located in the 
isthmus or neck region of the gastric gland. These cells proliferate, migrate up or 
down and differentiate and ultimately give rise to all cells of the gastric epithelium 
[10, 14].  
 
Knock-out studies for the gastrin gene (GAST) or CCK2 receptor gene (CCKBR) has 
confirmed that gastrin has a pivotal role in organization and maintenance of the 
gastric epithelium, as it regulates proliferation, migration and differentiation of cells 
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[10, 15-17]. Chen et al. [18] studied the morphology and function of ECL cells in 
CCK2 receptor- deficient mice and showed that the hypergastrinemic response is 
ineffective because of the target receptor is absent and thus preventing the receptor- 
signalling cascade. Knock-down of the receptor resulted in thinner oxyntic mucosa, 
absence of normal ECL cells and a reduction in parietal cells and impaired acid 
secretion. In the gastrin-deficient mice, Friis-Hansen et al. [16] found that the parietal 
cells was decreased in number and appeared to be immature and had reduced ability 
to secrete acid. In the same study they found that the acid secretion could be partly 
restored after 6 days of gastrin administration, and the number of mature parietal cells 
increased. 
 
Long-lasting conditions of hypergastrinemia has been shown to promote gastric 
adenocarcinoma in mice and the development of ECL cell hyperplasia and ultimately 
malignant carcinoids tumors [13]. In the transgenic mouse model INS-GAS, the 
gastrin expression is targeted to pancreatic β-cells. Initially these mice showed mild 
hypergastrinemia and increased proliferation in the gastric mucosa. Parietal cells 
increased in number and enhanced secretion of gastric acid. After 4 months, the 
parietal cells and acid secretion was lost and the mice developed hyperplasia. Older 
INS-GAS mice were predisposed to develop gastric cancer and infection with 
Helicobacter felis accelerates this development [19]. 
 
Hypergastrinemia and ECL cell carcinoids occur in humans with gastrin-secreting 
tumors (gastrinomas) and atrophic gastritis/or pernicious anaemia [20]. In atrophic 
gastritis there is a loss of parietal cells, which leads to loss of acid secretion, and 
consequently disrupting the normal inhibition of the G-cells. 30% of patients with 
gastrinoma and 5% of patients with gastritis or pernicious anaemia develops ECL cell 
carcinoids [20]. 
 
1.3 Gastrin and gastrointestinal cancer 
Since the mid-1980s, there has been an increasing interest in research of the role of 
gastrin in carcinogenesis [13]. Gastrin has been shown to be a growth factor in 
malignancies of the gastrointestinal tract, medullary thyroid cancer, and small lung 
cancer as well as tumors of the central and peripheral nervous system [17, 21].  
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Henwood et al. [22] studied the expression of gastrin and the CCK2 receptor in a 
stepwise progression monitoring premalignant changes within the gastric mucosa. 
Human tissue samples from patients showed an increased expression of both gastrin 
and the CCK2 receptor in atrophic gastritis to intestinal metaplasia, dysplasia, and 
gastric adenocarcinoma. The expression level of the receptor increased significantly 
from atropic gastritis to gastric adenocarcinoma with a median increase from 
approximately 5% to 34% of the tissue area [22]. In another study on gastric 
adenocarcinoma patients found gastrin and its receptor to be significantly related. The 
expression level of gastrin and the receptor was high in gastric adenocarcinoma tissue 
of patients, with approximately 48% gastrin positive and 57% CCK2 receptor positive 
tissue samples [23]. In the same study, gastrin and CCK2 receptor expression were 
not found to be significant prognostic factors, however the prognosis of patients 
positive for both gastrin and CCK2 receptor were significantly poorer than for those 
negative for gastrin and CCK2 receptor in diffuse-type gastric cancer patients. These 
results indicate that for this subgroup of gastric carcinoma, gastrin has a role as an 
autocrine growth factor [23]. Somatic mutations in CCK2 receptor gene have been 
identified in colorectal and gastric tumors and the changes affect cellular behaviour 
and promote tumor progression [24]. 
 
Gastrin might influence carcinogenesis through several signalling pathways. It 
mediates gene expression associated with cell division, invasion, angiogenesis and 
anti-apoptotic activity (figure 1.3) [13]. Gastrin binds to the CCK2 receptor and 
signalling via the Gq11- protein to activate several secondary messengers. At an early 
stage, activation of phospholipase C (PLC) results in the production of the secondary 
messengers inositol triphosphate (IP3) and diacylglycerol (DAG). These events result 
in intracellular Ca2+ release and activation of protein kinase C (PKC) [17]. Upon 
activation of CCK2 receptor through PKC-dependent mechanisms, the mitogen-
activated protein kinase (MAPK) pathways are activated [12]. MAPK pathways are 
central in regulating cell proliferation and migration in a gastrin mediated manner 
[12]. The phosphoinositide kinase 3 (PI3K) pathway, is involved in gastrin dependent 
cell proliferation and anti-apoptotic action of the CCK2 receptor, as well as regulation 
of migration and cell adhesion [12]. All together, these signalling pathways are 
important in carcinogenesis and associated with tumor progression and cell survival 
[12, 17, 25].  
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Figure 1.3. Gastrin mediates gene expression associated with a myriad of cellular functions. Upon 
activation of the CCK2R, several the signalling pathways are activated and that can influence the 
carcinogenesis (Modified from Watson et al. [13]). 
 
Several hundreds genes not known to be regulated by gastrin were identified by 
Selvik at al. [26] in our group as gastrin responsive genes in the pancreatic 
adenocarcinoma cell line AR42J. In this study it was found that gastrin treatment 
seemed to activate genes involved in ER stress/survival. These findings may improve 
the understanding of how gastrin affects pathophysiological processes [26]. NR4A2 
was one of the genes found to be a gastrin responsive gene, and thus became of 
interest to this group.  
 
1.4 NR4A2  
Nuclear receptor subfamily 4, group A, member 2 (NR4A2) is a transcription factor 
belonging to the orphan nuclear receptor family NR4A [27]. Receptor knock-down or 
overexpression in vivo and in vitro has demonstrated pro-oncogenic or suppressor-like 
activity of orphan receptors [28]. During the last couple of years, NR4A2 expression 
has been suggested as prognostic/predictive factors and potential therapeutic targets 
for patients with different cancer types including gastric cancer, colon cancer, bladder 
cancer, prostate cancer and breast cancer [28-34]. The biological functions of orphan 
nuclear receptors in tumors and the prognostic significance are incomplete and needs 
to be further studied. 
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The NR4A subgroup includes NR4A1 (Nur77), NR4A2 (Nurr1) and NR4A3 (Nor1). 
The NR4A nuclear receptors are expressed in skeletal muscle, adipose, heart, kidney, 
T-cells, liver and the brain [27, 35] and are important regulators of proliferation, 
apoptosis and differentiation [35]. The NR4As is involved in processes including 
cardiovascular disease, apoptosis, neurological disease, steroidogenesis, 
inflammation, metabolic disease and oncogenesis [36]. 
 
Nuclear receptors activates or repress target genes by binding directly to DNA 
response elements or by binding to other transcription factors [37]. NR4A2 binds to 
target genes either as a monomer, homodimer or heterodimer with e.g. retinoid X 
receptor (RXR) (figure 1.4). As a monomer the DNA binding site for all the three 
NR4A receptors is the NGFI-B response element (NBRE). As homodimers and 
heterodimers with other NR4A members, they bind to the Nur-responsive element 
(NurRE). NR4A1 and NR4A2 can in addition bind as a heterodimer with e.g. RXR 
receptor to the DR5 motif [38].  
 
 
Figure 1.4. DNA response elements recognized by NR4A2. NR4A2 is a transcription factor binding 
either as a monomer, homodimer or heterodimer with e.g. RXR to different DNA response elements 
(Modified from Decressac et al. [39]) 
 
The structural organization of the NR4As reveals that the three receptors have well-
conserved homologous DNA binding site (91-95%) and C-terminal ligand binding 
domain (60%), but a highly variable N-terminal (figure 1.5) [38].  
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Figure 1.5. NR4A have a common structural organization of their functional domains. The 
nuclear receptors compose of an amino-terminal activation domain AF-1, a DNA-binding domain 
(DBD) separated by a hinge region, and ligand-binding domain (LBD) with a short conserved helical 
sequence referred to as activation function 2 (AF-2) at the carboxyl-terminal end of the LBD [40] 
(From Safe et al. [38]) 
 
The NR4A2 ligand-binding domain (LBD) is folded in a way that resembles an 
agonist-bound, transcriptionally active LBD in nuclear receptors. X-ray crystal 
structure analysis of the LBD displays that NR4A2 does not have a typical ligand-
binding cavity, instead this space is occupied by tightly packed, bulky hydrophobic 
amino acid residue side chains. As these amino acids are conserved in this subfamily, 
it is predicted that all the members are ligand-independent transcription factors [41]. It 
has been shown by mutation analysis that the activity of the three receptors is 
independent of the LBD [35].  
 
A coactivator hydrophobic binding cleft is normally found in nuclear receptors, but in 
NR4A2 this interacting surface is significantly different. These findings indicate that 
NR4A2 is incapable to interact with a coactivator or a corepressor through the 
classical coactivator site of nuclear receptors [41]. Consequently, the transcriptional 
activity of these receptors is primarily dependent on the level of expression and 
posttranslational modifications [35]. Activation or deactivation of nuclear NR4A 
depends on posttranslational protein modifications such as phosphorylation, 
acetylation, ubiquitination and sumoylation that facilitate the recruitment of 
coactivators or corepressors [38]. NR4A2 is primarily phosphorylated by MAPK or 
AKT, and sumoylated by protein inhibitor of activated STAT-γ [42-44]. Several 
recent described agonists interacts with these receptors either by modulating the N-
terminal AF-1 domain or the C-terminal LBD [36].  
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Another important regulatory mechanism for transcriptional activity of the nuclear 
receptors is their subcellular localization and dynamic movement. Nuclear receptors 
and their co-regulators are known to translocate between the nucleus and the 
cytoplasm, thus the level of expression and the concentrations of the co-regulators 
gives an additional level of regulation [45]. The shuttling of NR4A2 in and out of the 
nucleus is regulated by a nuclear localization signal (NLS) within the DNA binding 
domain and two nuclear export signals (NES) in the ligand-binding domain. Upon 
oxidative stress, NR4A2 was distributed and found to accumulate in the cytosol thus 
reduceing expression of NR4A2-dependent genes and loss of phenotype of the 
dopaminergic cell line MN9D [46].  
 
1.5 The role of NR4A2 in cancer 
The NR4A subgroup are immediate early response genes that are induced by a 
various range of physiological and physical stimuli [27]. These include 
prostaglandins, fatty acids, growth factors, neurotransmitters, hormonally-active 
peptides, and other cellular stressors such as fluid sheer stress, and membrane 
depolarization [38]. NR4A2 emerges as an important regulatory node in biological 
networks and is characterized as a hub gene. Activation of NR4A receptors is 
regulated by several kinase pathways and they have been recognized as molecular 
switches in apoptosis, DNA-repair, proliferation, migration, inflammation, 
metabolism and angiogenesis, altogether being processes associated with 
carcinogenesis (figure 1.6) [47].  
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Figure 1.6. The NR4A receptors are involved in various cellular functions that are important in 
carcinogenesis. A various range of stimuli activate the NR4A receptors, and upon activation they act 
as transcription factors and alter the expression of downstream genes modulated by multiple signalling 
pathways. Apoptosis, proliferation, angiogenesis, DNA repair and fatty acid metabolism are all 
important features in cancer and during cellular stress (From Mohan et al. [47]). 
 
It has been found that orphan transcription factors may serve as both positive and 
negative prognostic factor depending on the cancer type. Overall, the NR4A2 receptor 
seems to exhibit oncogenic activity in most cancer types, but functional and 
prognostic studies are limited and needs to be further studied [28]. Inamoto et al. [30] 
investigated the clinicopathologic relevance of NR4A2 in a cohort of bladder cancer 
patients. They found that NR4A2 expression was higher in cancer patients compared 
to healthy controls. Higher levels of cytoplasmic NR4A2 correlated with distant 
metastasis and lower patient survival. They also found that increased expression of 
NR4A2 in tumor cells correlated with increased tumor stage and an invasive growth 
pattern [30]. In breast cancer etiology, the NR4A2 receptors appear to have a 
dichotomous role. NR4A2 is higher expressed in normal breast epithelium compared 
to breast cancer tissue, and therefore loss of NR4A2 expression is associated with 
oncogenic transformation of the breast epithelium. In the same study, they found that 
breast cancer patients with lymph node metastasis had a lower NR4A2 expression. 
Contradictory, NR4A2 silenced breast xenografts showed a significant decreased 
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growth compared to the control [32]. This suggests that its role may be impacted by 
the cellular context and stage of carcinogenesis and specific protein-protein 
interactions in its role in mediating malignancies [32]. 
 
Recent studies show that NR4A2 expression predicts poor prognosis and drug 
resistance in colon and gastric cancer [29, 34]. NR4A2 expression predicted an 
unfavourable prognosis, especially for those who received chemotherapy, after 
curative surgery of patients with gastric cancer. This study indicate that NR4A2 might 
serve as a prognostic and predictive factor for patients with gastric cancer [29]. 
NR4A2 appears as an important factor linking inflammation and cancer [33, 47]. 
Aberrant expression of NR4A2 activates several signalling pathways related to 
inflammation and promotes the development and progression of gastrointestinal 
cancers [33]. Cyclooxygenase-2 (COX-2) is up-regulated in inflammation and cancer, 
and induces the production of pro-inflammatory prostaglandin E2 (PGE2) [33]. In 
colorectal cancer, NR4A2 is up-regulated in vivo and in vitro upon PGE2 treatment in 
a cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA)-dependent 
manner, and contribute to the survival of colorectal cancer cell by inhibiting apoptosis 
[48]. It has also been shown in colorectal cancer that NR4A2 activates the promoter 
of osteopontin (OPN). OPN is a direct target of the Wnt-signalling pathway and is 
known to promote tumor progression and is involved in processes like invasion, 
metastasis and angiogenesis in colorectal cancer [29, 49]. Blocking of the NR4A2 and 
the Wnt-signalling pathway appear to be involved in the anti-tumor activity of COX-2 
inhibitors [49]. 
 
NR4A2 has been characterized as a hub gene associated with liver metastasis, and 
suggested as a tumor suppressor in gastric cancer. Both the transcriptional and 
translational level of NR4A2 was significantly down-regulated in liver metastasis 
compared to the paired primary tumor [50]. In our group, experiments performed by 
Misund et al. [51] found that gastrin induced NR4A2 gene expression in a PKA and 
PKC dependent manner in the gastric adenocarcinoma cell line AGS-GR. Endogenous 
NR4A2 was also observed in vivo in normal gastric mucosa in the ECL cells. Since 
the ECL cells possess the CCK2 receptor this further confirms that NR4A2 
expression is activated by gastrin [51]. In the same study, knock-down experiments 
with siRNA targeting NR4A2 increased migration of gastrin treated adenocarcinoma 
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cell, while ectopically expressed NR4A2 increased apoptosis and hampered gastrin 
induced invasion, indicating a tumor suppressor function of NR4A2. Gastrin also 
affected the nucleus-cytosol shuttling of NR4A2 in these cells, higher amounts of 
NR4A2 were localized to cytoplasm upon gastrin stimulation [51]. Therefore it is of 
interest to find protein-interacting partners of NR4A2 in gastric adenocarcinoma cells.  
  
	  	  
 14	  
 
  
	  	  
 15	  
1.6 Aim of the study 
The transcription factor NR4A2 has been reported to play an ambiguous role in 
carcinogenesis. Recent studies indicate that NR4A2 protein-protein interactions and 
sub-cellular localization of NR4A2 are of vital importance when it comes to specific 
cellular responses. Gastrin has been shown to induce the expression of NR4A2 and 
also modifies its nucleus-cytosol shuttling in the gastric adenocarcinoma cell line 
AGS-GR.  
 
The overall aim of this study was to characterize protein-binding partners of NR4A2. 
We hypothesized that gastrin stimulation would affect the binding partners of 
NR4A2, and thus examined gastrin treated MKN45 cells. The HEK293 cells were 
included as a non-gastric-cancer cell line.  
 
The aim of the study was: 
 
• Characterize the NR4A2 expression and CCK2 receptor expression in gastric 
cancer cell lines to further establish a cell line model that could be used to 
elucidate the role of gastrin-mediated NR4A2 expression and function 
• Establish transient transfection of NR4A2 in appropriate cell lines  
• Examine NR4A2 bindings partners by immunoprecipitation (IP) and Western 
blot 
• Utilize a proteomic approach with Mass Spectrometry on the IP samples to 
characterize protein-protein interactions 
• Validate the proteins by IP and Western blot 
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2. Material and methods  
2.1 Cell lines and reagents 
Cells were incubated in a humidified environment of 5% pCO2 and at 37°C. The 
growth medium was added 100 U/ml penicillin, 100 µg/ml streptomycine and 1 µg/ml 
Fungizone (all from Gibco, Life Technologies). 
 
The human cell line KATO-III cells is derived from signet-ring cells of gastric 
carcinoma and was purchased from American Type Culture Collection (ATCC) and 
grown in RPMI-1640 medium (Sigma) with 20% fetal calf serum (FCS) (Sigma). 
HEK293 cells (ATCC) are derived from human embryonic kidney. The MKN45 cells 
are derived from a poorly differentiated adenocarcinoma of the stomach, provided 
from Prof. Sue Watson (Department of Surgery Queens Medical Centre University 
Hospital Nottingham, UK). HEK293 cells and MKN45 cells were both grown in 
Dulbecco’s Modified Eagle Medium (DMEM) (Gibco) with 10% FCS.  
 
pEGFP-NR4A2 (appendix 1) and pEGFP plasmids were kindly provided by BSc 
Kevin McMahon, University Collage Dublin, Ireland. The NR4A2-pCMX and pCMX 
plasmids were a gift from Prof. Thomas Perlmann, Karolinska Institute, Sweden. 
 
Gastrin (G-17) was purchased from Sigma-Aldrich. 
2.2 Seeding of cells  
The medium was removed and the cells were washed with 0.25% trypsin with EDTA 
(Gibco), and subsequently incubated with trypsin at 37°C. To deactivate the trypsin, 
growth medium with FCS was added. The cells were then collected and centrifuged 
(120x g, 8 minutes) and the cell pellet further dissolved in 10 ml of media. Table 2.1 
gives an overview of the number of cells seeded in the different plates.  
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Table 2.1. Number of cells seeded. 
Cell line 
Number of cells 
96 well plate 6 well plate 100 mm2 petri dish Lab-Tek 8 well 
MKN45 0.01x 106 0.3-0.4x 106 1.5x 106 0.05x 106 
HEK293 0.02x 106 0.3x 106 2.0x 106  
KATO-III  0.45x 106   	  
2.3 Purification of EGFP-NR4A2 plasmid 
EGFP-NR4A2 plasmids were kept in a glycerol stock at -80°C. A small amount of the 
bacteria in the glycerol stock was picked (using a pipette tip), inoculated in 3 ml LB 
broth containing 30µg/µl kanamycin (Sigma) and incubated with vigorous shaking 
(37°C, over night). The Qiagen Plasmid Maxi Kit (Qiagen) was used to purify the 
plasmids. The protocol from the manufacturer was followed.  
 
The DNA concentration was measured by Nanodrop spectrophotometer (Thermo 
Scientific) at 260 nm.  
  
2.4 Transfection of cells  
The cells were seeded in six-well plates or 100mm2 petri dishes according to table 
2.1, and incubated for 24-48 hours. To transfect cells, different amount of DNA and 
Metafectene PRO (Biontex) were used for the various cell lines (table 2.2). Plasmids 
and Metafectene PRO were diluted in growth medium without serum, mixed together 
and incubated at room temperature (15-20 minutes) before added to the cells. After 4-
6 hours the medium was replaced with medium with or without serum. 24-48 hours 
post transfection the transfection efficiency was assessed using IX71 inverted 
microscope (Olympus).   
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Table 2.2. The transfection protocol used for MKN45 and HEK293 cells.  
 
6 well plate 100 mm2 petri dish 
DNA 
(µg) 
Metafectene 
PRO (µl) 
Transfection 
efficiency 
DNA 
(µg) 
Metafectene 
PRO (µl) 
Transfection 
efficiency 
MKN45 
pEGFP-NR4A2 2.5 7 50% 20,0 60,0 50-60% 
pGFP 2.5 7 60% 20,0 60,0 50-60 % 
pCMX 2.5 7     
HEK293  
A. pEGFP-NR4A2 2.0 4.0 70% 13.0 40.0 90% 
B. pEGFP-NR4A2 2.5 6.0 80%    
C. pEGFP-NR4A2 3.0 9.0 80%    
D. pEGFP-NR4A2 3.5 10.5 80%    
pEGFP 2.5 6.0 90% 13.0 40.0 90% 
 
2.5 Western blot  
The cells were serum-starved before treated with 10 nM gastrin. The medium was 
then removed and the cells were washed and incubated with trypsin. To deactivate the 
trypsin, cold PBS (Thermo Scientific) with 10% FCS was added. The cells were 
harvested and centrifuged (430x g, 8 minutes). The cell pellet was resuspended in 1 
ml PBS with 10% FCS and centrifuged at 4°C (430x g, 8 minutes). Further, the cells 
were lysed in Urea lysis-buffer ((8M Urea (Sigma), 0.50% Triton x100 (VWR), 0.1 M 
DTT (Sigma Aldrich), protease inhibitor cocktails 1x Complete (PI) (Roche), 5x PIC2 
(Sigma), 5x PIC3 (Sigma)) by adding 2x the volume of the cell pellet, vortexed (30 
seconds multiple times), and subsequently centrifuged at 4°C (16 000x g, 16 
minutes).  
 
Bio-Rad Protein Assay Dye Reagent Concentrate (BioRad Laboratories) was used to 
estimate the protein concentration of the samples. 1 µl of the sample was diluted in 1 
ml of Bio-Rad solution (diluted 1:5 in H2O) and vortexed. The absorbance was 
measured at 595 nm (Shimadzu Spectrophotometer). To determine the protein 
concentration the mean absorbance value of three replicates were calculated from a 
standard curve generated in Bovine serum albumin (BSA) (Sigma). The samples were 
then stored at – 80°C.  
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When running the gel; protein samples (amount provided in table 2.3) were mixed 
with NuPAGE LDS Sample Buffer (Invitrogen Life Technologies) and diluted with 
dH2O to obtain equal volume of the samples and subsequently denatured at 70°C (10 
minutes). The NuPAGE 10% BisTris SDS Mini Polyacrylamide gel (Invitrogen) was 
run with 1x NuPAGE MOPS SDS Running Buffer (Invitrogen) with 200 V (1 hour 
and 15 minutes). MagicMark XP Western Protein Standard (Novex) and 
Kaleidoscope™ prestained standards (Bio-Rad) were used as standard size markers.  
 
Table 2.3. The amount of protein loaded onto the gel for detection by Western blot. 
Cell line 
Protein loaded (µg) 
CCK2 receptor NR4A2 EGFP-NR4A2 
MKN45 60 85 50 
KATO-III  60 60  
AGS-GR 60   
HEK293 60  30 
 
The PVDF Immobilon-P membrane (pore size 0.45 µm) (Millipore Immobilon®) was 
activated with methanol (30 seconds) and washed in dH2O and kept at 4°C in 1x 
NuPAGE Transfer Buffer supplemented with 10% methanol and 0.1% NuPAGE 
antioxidant (Invitrogen) until used. The proteins were transferred on to the PVDF-
membrane by using Xcell II Blot Module (Invitrogen) with the use of Transfer Buffer 
and run with 30 V (1 hour and 10 minutes).  
 
To visualize the success of the transfer of proteins on the PVDF membrane, a 
reversible membrane staining (30 seconds) was performed with Ponceau S Staining 
Solution (0.1% Ponceau S (Sigma- Aldrich) in 5% acetic acid). The membrane was 
subsequently washed in TBST (1M Trizma base (Sigma- Aldrich), 18% NaCl (Merck, 
Millipore), 0.1% Tween 20 (VWR)) and blocked with 5% non-fat dry milk (Nestle) in 
TBST (2 hours or longer if problems with unspecific bands). After blocking, the 
membrane was washed in TBST (3x 10 minutes). The membrane was incubated with 
the primary antibody (table 2.4), diluted in 5% non-fat dry milk in TBST or 1% BSA 
in TBST (2 hours in room temperature or at 4°C over night). Before adding secondary 
antibody, the membrane was washed with TBST (3x 10 minutes). The horse-radish 
peroxidase-conjugated secondary antibody was diluted in 5% non-fat dry milk in 
TBST and the membrane was incubated at room temperature (1 hour and 30 minutes).  
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Table 2.4. Antibodies used in Western blotting. 
Antibody Molecular weight (kDa) Company   .   Dilution Diluent 
Primary 
GFP 27  Abcam  1:2000 1% BSA 
NR4A2 66  Abcam 1:1000 5% non-fat dry milk  
CREB 43  Cell Signaling  1:1000 5% non-fat dry milk  
TCF4 58,79  Cell Signaling 1:1000 5% non-fat dry milk  
TORC2 79-85  Calbiochem 1:2000 5% non-fat dry milk 
CCKBR 48  Abcam 1:1000 5% non-fat dry milk  
β-catenin 92  Cell Signaling  1:1000 5% non-fat dry milk  
α-tubulin 55  Santa Cruz 1:1000 5% non-fat dry milk  
GAPDH 36  Abcam  1:5000 5% non-fat dry milk  
LKB1 54  Cell Signaling 1:1000 5% non-fat dry milk 
Secondary 
Goat anti-mouse  Dako Denmark AS 1:5000 5% non-fat dry milk 
Hoarse anti-rabbit  Thermo Science 1:5000 5% non-fat dry milk  
 
The membrane was further washed in TBST (3x 10 minutes). To detect the proteins 
on the membrane SuperSignal® West Femto Substrate Maximum Sensitivity 
Substrate (Thermo Scientific) system was used. The incubation time with the 
substrate varied depending on the protein (40 seconds to 5 minutes) and the blots 
were imaged by Kodak Image Station 2000R (Kodak) or with Odyssey FC (LI-COR). 
To quantify the proteins, Kodak Molecular Imaging software or Image Studio was 
used. The relative expression levels of the proteins were detected by normalizing to α-
tubulin or GAPDH and graphs were made in Prism 6 (GraphPad).  
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2.6 Immunoprecipitation (IP) 
Immunoprecipitation is a method for precipitating proteins using an antibody that 
specifically binds the protein of interest (figure 2.1). It is possible to precipitate intact 
protein complexes, also known as co-IP. IP is a technique used for detection of 
protein-protein interactions [52].  
  
 
Figure 2.1. Immunoprecipitation (IP). Magnetic beads coupled to specific antibodies are incubated 
with the sample containing the protein of interest. Following an incubation period, the protein will bind 
to the bead-antibody complex. By use of a magnetic rack, the bead-antibody-protein complex 
immobilises to one side of the tube and allow for removal of the supernatant. The antigen can then be 
separated from the beads by heating.  
 
2.6.1 Coupling of anti-GFP to Dynabeads 
200 µl protein Dynabeads Protein A (Invitrogen) was washed 3x in 1 ml 0.1 M Na-
phosphate buffer (pH 7.5) (Riedel de Haên) using a magnetic rack. The antibody 
solution was prepared by adding 10 µg anti-GFP (affinity-purified rabbit polyclonal 
antibody raised against GFP protein) per 100 µl diluted in Na-phosphate buffer. The 
beads were incubated in room temperature with antibody on a roller (1 hour). The 
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beads were then washed 3x in 1 ml Na-phosphate buffer, 2x in 1 ml 0.2 M 
Trietanolamine (pH 8.2) (Sigma) and incubated with Dimethyl pimelimidate 
dihydrochloride (DMP)-solution (10 mg DMP (Sigma) per 100 µl beads, dissolved in 
1 ml Trietanolamine) (45 minutes). The beads were washed in 1 ml 0.1 M 
Etanolamine (pH 8.2) (Sigma) and then incubated with 1 ml Etanolamine (1 hour). 
Finally, the beads were then washed 3x in 1 ml PBS, and resuspended in 200 µl PBS 
with 0.1% Tween and stored at 4 °C. 
 
2.6.2 Immunoprecipitation 
HEK293 and MKN45 cells were seeded in 100mm2 petri dishes according to table 
2.1. The HEK293 cells were incubated for 48 hours, and transfected according to 
table 2.2, and serum starved for 24 hours. The MKN45 cells were incubated for 24 
hours, and transfected according to table 2.2. The cells were starved for 48 hours prior 
to treatment with 10 nM gastrin (2 and 4 hours).  
 
The cells were lysed in IP lysis-buffer (10 mM Tris (Sigma), 200 mM KCl (Sigma), 2 
mM EDTA (Gibco), 40% Glycerol (Merk, Millipore), 0,5% NP40, 2 mM DTT, 10 
mM MgCl2 (Fluka), dH2O, protease inhibitor cocktails 1x Complete (PI), 5x PIC2, 5x 
PIC3). The lysates were made following the same procedure as Western blot and the 
IP lysis-buffer was added 2x the volume of the cell pellet. The tubes were placed on 
the roller for 2 hours and vortexed (30 seconds) every 20-30 minutes. The cells were 
centrifuged at 4°C (16000x g, 16 minutes) and stored at -80 °C.  	  
200 µg of protein was solved in 10 mM Tris (pH 7.5), to a total volume of 100 µl. 15 
µl Dynabeads Protein A precoated with anti-GFP was washed in 1 ml Tris, and 
resuspended in 100 µl Tris. The beads and the proteins lysate were mixed and 
incubated at 4°C on a roller (over night). The beads were washed 3x in 500 µl Tris 
and 20 µl of loading buffer (10x DTT, 4x LDS, dH2O) was added and incubated at 
70°C (10 minutes). The beads were then removed and the samples were analysed with 
Western blot. For the MKN45 cells 40 µg of the cell lysate was included as input for 
the MKN45 cells, and 30 µg was used for the HEK293 cells. Lysate from AGS-GR 
cells transfected with pEGFP-NR4A2 (10 µg) was used as a positive control for the 
NR4A2 antibody. 
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2.7 Mass Spectrometry analysis of proteins 
In the first biological experiment, 200 µg of protein was used for immunoprecipitation 
by guidance from the Proteomics and Metabolomics Core Facility (PROMEC), 
NTNU. However, the results indicated that more proteins were needed to investigate 
protein-protein interactions. After normalisation of the MS raw-data, only a few 
proteins were detected and therefore the experiment had to be repeated. 
 
In the second biological experiment, the HEK293 and MKN45 cells were seeded and 
transfected as described for IP. The cells were starved for 24 hours prior to 
stimulation with 10 nM gastrin (30 minutes). 1000 µg of protein was incubated with 
20 µg Dynabeads Protein A at 4°C (over night). To optimise the washing buffer 50 
mM KCl was added to increase the stringency of the buffer. The samples were 
resuspended in loading buffer as described for IP and analysed at PROMEC. The 
method is briefly described as follows: The samples were run on a 10% Invitrogen 
Novex gel (Invitrogen), stained with Comassie Blue, and cut into three fractions. The 
Mass Spectrometry analysis was run on Orbitrap Elite (Thermo Scientific) with three 
technical replicates of each sample. The samples were analysed using Mascot and 
Sequest with threshold values of ≥ 5 and ≥ 1 for scores respectively and false 
discovery rate ≤ 0.05. Mascot uses a statistical and geometric probability-based 
scoring method for scoring peptides, while Sequest uses descriptive parameters and 
correlative matching of peptide fragments to score peptides [53]. 
 
The samples were normalised and the log2 ratio was calculated. Network and 
functional analyses were performed through the use of Ingenuity Pathway Analysis 
(IPA) (http://ingenuity.com). The criterion used was a log2 ratio ≥ 0.58. IPA uses 
Fisher’s Exact test to calculate the p-values. P-values ≤ 0.05 were considered 
significant. For the networks, a p-score is presented, and is defined as: 
 p-score = -log10 (p-value).  
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2.8 qRT-PCR  
MKN45 cells were seeded in 6 well plates according to table 2.1, serum-starved and 
stimulated with 10 nM gastrin (30 minutes, 1, 2, 3, and 6 hours). The cells were lysed 
directly in the wells by adding 350 µl RLT-lysis buffer (1 µl β-merceptoethanol 
(VWR) per 1ml RLT (Qiagen)) to each well. The cell lysate was collected and stored 
at -80 °C.  
 
Total RNA was extracted using RNeasy Mini Kit (Qiagen) according to the protocol 
recommended by the manufacturer. RNA quality and quantity were evaluated with 
Nanodrop spectrophotometer.  
 
cDNA synthesis was performed using Transcriptor First Strand cDNA Synthesis Kit 
(Roche), with 1 µg total RNA and a total volume of 20 µl of the reaction mix. As a 
negative control reverse transcriptase was omitted and replaced with dH2O. The 
cDNA was diluted 1:2 in RNase free water, and stored at -20°C.  
 
qRT-PCR was performed using Fast Start Universal SYBR Green master (Rox), 
(Roche). The protocol was followed using 2 µg cDNA, 200 nM of the primers with a 
total volume of 20 µl of the reaction mix. The primer sequences used are shown in 
table 2.5.  
 
Table 2.5. Primers used in qRT-PCR. 
Primer Sequence 
NR4A2 
NR4A2 forward  5´-GTCTCAGCTGCTCGACACG-3´ 
NR4A2 reverse  5´- TTTTGCACTGTGTCGCTTAAA-3´ 
β-actin 
β-actin forward  5´- TGAGCGCGGCTACAGCTT-3´ 
β-actin reverse  5´- CCTTAATGTCACGCACGATTT-3´ 
 
Real-time PCR was performed in Life Technologies StepOnePlus Real-Time PCR 
System: 5 minutes at 95°C, 40 cycles of 30 seconds at 95°C, 30 seconds at 60°C, 30 
seconds at 72°C. Melt curve analysis was also performed with 15 seconds at 95°C, 1 
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minute in 60°C, and then increasing temperature by 0.3°C per second up to 95°C, and 
finally 15 seconds at 95°C. The melt curve is shown in appendix 2.  
 
The PCR samples were run in triplicates and the expression levels were normalized to 
β-actin. The average CT-value was used for further quantification, and the ΔΔCT- 
method [54] was used to calculate the relative expression rate of the gene of interest. 
Data is presented as mean ± S.D and graphs were made in Prism 6 (GraphPad).  
2.9 Immunocytochemistry  
MKN45 cells were seeded in Lab-TekTM Chambered Coverglass with 8 wells 
(NUNC, Thermo Scientific) according to table 2.1 and incubated for 24 hours. The 
cells were fixated in 4% paraformaldehyde (Merck), and incubated at room 
temperature (10 minutes). The wells were washed with PBS. Ice-cold methanol was 
added to permeabilize the cells and the wells were incubated on ice (10 minutes). The 
methanol was removed and the wells were washed in PBS, and incubated with 
blocking solution (3% goat serum blocking solution (Gibco) in PBS) and incubated at 
4°C (over night).  
 
The cells were incubated with primary antibody on a shaker at room temperature (1 
hour) and washed in PBS (3x 10 minutes). The cells were then incubated with the 
secondary antibody (1 hour), and protected from light. Antibodies used are presented 
in table 2.6.  
 
Table 2.6. Antibodies used in confocal microscopy.  
Antibody Molecular weight (kDa) Company Dilution Diluent 
Primary 
CCK2R 48 kDa Abbiotech 1:200 1% goat serum in PBS 
CCK2R 48 kDa Abcam 1:300 1% goat serum in PBS 
Secondary 
Alexa 488  Invitrogen 1:5000 1% goat serum in PBS 
 
The wells were further washed with PBS (4x 10 minutes) and in addition nuclear 
stained with Draq-5 (5 µM in PBS) (AH Diagnostics) by adding 100 µl to each well 
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and incubated on a shaker (5 minutes). The Draq-5 solution was removed and cold 
200 µl PBS was added before confocal microscopy using LSM 510 META (Zeiss).  
2.10 MTT – assay  
MTT is a colorimetric viability assay that measures the reduction of yellow 3-(4,5-
dimethythiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) to a dark purple 
colored formazan product [55].  
 
HEK293 and MKN45 were seeded in 96-well plates according to table 2.1, and 
cultivated for 24 hours. The cells were then transfected with 0.1 µg plasmid and 0.5 µl 
Metafectene PRO/ well. The MTT stock solution (500 mg in 100 ml PBS) (Sigma) 
was diluted 1:5 in media without serum and was added into each well 48 hours after 
transfection and incubated at 37°C (4 hours). 130 µl of the medium was removed and 
100 µl of Isopropanol (Kemetyl) (acidified to 37 % with HCl) was added before 
incubation on a shaker (1 hour). The absorbance of formazan was measured 
spectrophotometrically at 570 nm. 
 
Possible statistical significance between the transfected cells were identified using a 
two-tailed independent Student´s t-test in Excel. P-value ≤ 0.05 was considered 
significant.  	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3. Results 
3.1 The CCK2 receptor is expressed in MKN45 and KATO-III cells  
Initially, we wanted to establish a cell line model that could easily be transfected and 
at the same represent as a model to study gastrin mediated NR4A2 regulation. Since 
only a few studies have shown the expression of the CCK2 receptor in gastric cancer 
cell-lines [56], and seldom at the protein level, we examined the expression in 
MKN45 and KATO-III cells by Western blot. 
 
The CCK2 receptor was detected in both cell lines, utilizing the CCK2 receptor 
antibody from Abcam (figure 3.1 upper panel). The antibody showed some non-
specific bindings, but a band at approximately 48 kDa was detected and believed to be 
the correct band. The strongest expression of the CCK2 receptor was observed in 
MKN45 cells, while the expression in KATO-III cells was rather weak. This is in 
accordance with other studies. The KATO-III cells has been reported to express both 
gastrin and the CCK2 receptor mRNA, and upon gastrin stimulation, the expression 
of genes associated with cell growth and anti-apoptotic effect are induced [57]. The 
MKN45 cells have been shown to be gastrin responsive and initiate mitogenic 
response to gastrin [58-60]. These studies are in contrast to McWilliams	  et	  al. [56] 
who did not detect the CCK2 receptor in the MKN45 cells. As expected, no bands 
were observed in HEK293 cells. Western blot was also performed with the CCK2R 
antibody from Abbiotech, but yield poor results (data not shown). 
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Figure 3.1. The CCK2 receptor expression in the gastric carcinoma cell lines MKN45 and 
KATO-III. HEK293 cells were included as a control. The data represent one of two independent 
experiments.  
 
3.1.1 The expression of the CCK2 receptor determined by immunocytochemistry 
Further we examined the expression of the CCK2 receptor using 
immunocytochemistry and confocal microscopy imaging. In this experiment two 
different antibodies targeting the CCK2 receptor were used (antibodies from 
Abbiotech and Abcam, respectively), while Alexa 488 was used as secondary 
antibody. The CCK2 receptor is expressed in the cytoplasm and/or plasma membrane 
of the MKN45 cells (figure 3.2A). The antibody from Abbiotech seems to be the most 
suitable for confocal imaging as the staining pattern was considerably stronger 
compared to almost no expression using antibodies from Abcam (figure 3.2B). 
Negative controls without the primary antibody showed no staining.  
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Figure 3.2. The CCK2 receptor expression in MKN45 cells. The cells were fixed and stained for the 
CCK2 receptor by using antibodies from Abbiotech and Abcam (A and B, respectively). The cells were 
co-stained with Draq-5 (red) and visualized with Alexa 488 antibodies (green) by confocal microscopy 
(63x magnification). 
 
The AGS-GR cells are stabile transfected with the CCK2-receptor [61] and confocal 
imaging of the CCK2 receptor with the Abbiotech show high expression of the 
receptor using the antibody from Abbiotech (figure 3.3.). 
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Figure 3.3. The CCK2 receptor expression in AGS-GR cells. The cells were fixed and stained for the 
CCK2 receptor by using antibodies from Abbiotech. The cells were co-stained with Draq-5 (red) and 
visualized with Alexa 488 antibodies (green) by confocal microscopy (63x magnification). 
(Experiment performed by PhD fellow Shalini Rao) 
 
3.1.2 Gastrin induces CCK2 receptor expression in MKN45 cells 
Some studies have shown that gastrin can induce the expression of CCK2 receptor 
both at the mRNA [26, 62] and the protein level both in vitro and in vivo [62]. It was 
therefore of interest to investigate the expression of the CCK2 receptor upon gastrin 
stimulation in MKN45 and AGS-GR cells. 
 
The results indicate that gastrin induces the level of CCK2 receptor both in MKN45 
and AGS-GR cells. An increase in the protein level are observed after 8 hours of 
gastrin stimulation both cell lines (figure 3.4). The results are in agreement with the 
findings reported that the mRNA level increase upon gastrin stimulation in the AGS-
GR cells [26, 62], but has not been previously shown at protein level either in the 
AGS-GR or in the MKN45 cells. The AGS-GR cells were included as a positive 
control, but did not express a strong band as expected, although they express high 
levels of the receptor (figure 3.3). 
Abcam                                     Draq-5                           CCK2R!                            Merged!B!
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Figure 3.4. Gastrin induced CCK2 receptor expression in MKN45 and AGS-GR cells. The cells 
were stimulated with gastrin (10 nM) for the time points indicated. HEK293 cells were included as a 
control. The data represents one of two independent experiments. 
3.2 The NR4A2 expression in gastric carcinomas cell lines 
We have previously shown that NR4A2 is a gastrin responsive gene in the AGS-GR 
and AR42J cell lines [26, 51]. In the present study we investigated whether gastrin 
induced NR4A2 expression in MKN45 and KATO-III cells.  
 
The mRNA expression of NR4A2 was transiently induced by gastrin with the highest 
expression after one hour and with a decrease to baseline after three hours (Figure 
3.5A). The NR4A2 protein expression was confirmed by Western blot (figure 3.5B), 
and showed a peak after three hours with a subsequently decline. The expression 
pattern is representative of early response genes and the NR4A2 kinetic shown here is 
also reported by others [48, 51, 63]. Our results identify NR4A2 as a gastrin 
responsive gene in the adenocarcinoma cell line MKN45. 
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Figure 3.5. Gastrin induced NR4A2 expression in MKN45 cells. A: The cells were treated with 
gastrin (10 nM) and the mRNA levels of NR4A2 were measured with qRT-PCR. The data shown are 
mean ± SD. The data represent one of two biological experiments using three technical replicates. B: 
Western blot showing gastrin induced NR4A2 in MKN45 cells. AGS-GR cells transiently transfected 
with pEGFP-NR4A2 were used as control. The data represent one of two independent experiments. 
 
We next examined gastrin-induced expression of NR4A2 in KATO-III cells. The 
expression of NR4A2 was undetectable (figure 3.6). Therefore, no further 
experiments were performed in this cell line.  
 
 
Figure 3.6. Gastrin does not induced NR4A2 expression in KATO-III cells. The cells were 
stimulated with gastrin (10 nM). Western blot showing no expression of NR4A2. AGS-GR cells 
transiently transfected with pEGFP-NR4A2 were used as control.  
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3.3 Overexpression of NR4A2 in MKN45 cells and HEK293 cells  
Since previous results showed low levels of NR4A2 in untreated MKN45 cells, and 
we wanted to perform IP to identify protein-protein interaction partners of NR4A2 we 
transiently transfected the cells with the expression plasmid with recombinant EGFP 
tagged NR4A2, pEGFP-NR4A2. The HEK293 cells were included as a non-gastric-
cancer cell line as it was of interest to find novel interaction partners of NR4A2 
regardless of cell line. 
 
The transfection efficiency was determined by fluorescence microscopy, and in the 
MKN45 cells the number of transfected cells was estimated to be approximately 50-
60% (figure 3.7A). Further, the transfection protocol for the HEK293 cell was 
optimised by using different amounts of plasmid and Metafectene PRO (see table 2.2 
in “material and method” for details). The transfection condition “B” corresponding 
to 2.5 µg DNA and 6 µl Metafectene PRO, resulted in 80-90% transfection efficiency 
(figure 3.7B). When transfecting cells in 100 mm petri dishes, 13 µg DNA and 40 µl 
Metafectene PRO were used and resulted in 90% transfection efficiency. 
Overexpression of the EGFP-NR4A2 protein (93 kDa) was detected in both the cell 
lines determined by Western blotting (figure 3.8 A and B). 	  
 
As NR4A2 overexpression has shown to increase apoptosis in the AGS-GR cells [51], 
we wanted to examine the cell viability of the transfected cells, using MTT assay. No 
significant differences (p-value ≤ 0.05) in cell viability were detected in MKN45 or 
HEK293 cells, appendix 3.  
 
Figure	   3.7.	   Overexpression	   of	   NR4A2	   in	   transiently	   transfected	   cells.	   MKN45	   cells	   and	  HEK293	   cells	   (A	   and	   B,	   respectively)	   were	   transfected	   with	   pEGFP-­‐NR4A2	   and	   visualised	   by	  inverted	   fluorescence	  microscopy	   (400x	  magnification)	  before	   and	  after	  use	  of	   the	  EGFP	   filter,	  left	  and	  right	  panel	  respectively.	   
A! B!
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Figure	  3.8.	  Expression	  of	  EGFP-­‐NR4A2.	  A:	  MKN45	  cells	  were	  transfected	  with	  pEGFP-­‐NR4A2,	  pEGFP	  or	  pCMX	  and	  the	  expression	  of	  EGFP-­‐NR4A2	  was	  validated	  by	  Western	  blot.	  B:	  HEK293	  cells	  were	   transfected	  with	   pEGFP	   and	   pEGFP-­‐NR4A2	  with	   different	   ratios	   of	   the	   plasmid	   and	  metafectene	  PRO	  (A,	  B,	  C,	  D)	  as	  described	  in	  table	  2.2	  in	  “Material	  and	  method”.	  The	  expression	  of	  EGFP-­‐NR4A2	  was	  determined	  by	  Western	  blot.	  	  
3.4 NR4A2 does not bind to CREB or β-catenin  
To elucidate the role of NR4A2 in MKN45 cells it was of interest to characterize 
interaction partners of NR4A2. Initially immunoprecipitation was performed with 
antibodies targeting proteins known from the literature to be crucial in gastric 
adenocarcinoma cells. The Wnt/β-catenin signalling pathway is often deregulated in 
gastric cancer [64, 65]. Some nuclear receptors, e.g. the androgen receptor (AR) are 
known to modulate the Wnt-signalling pathway by interactions with β-catenin 
directly, whereas others have shown to bind to other members of the signalling 
pathway including Wnt, T cell factors (TCF) or glycogen synthase kinase-3 β 
(GSK3β) [66]. We therefore investigated whether a direct interaction could be found 
between NR4A2 and β-catenin or TCF4. Moreover, cAMP response element-binging 
protein (CREB) is a transcription factor shown by our group and others to play a role 
in gastrin-mediated signalling [67, 68] and is involved in cellular responses like 
growth and survival [69]. It was therefore of interest to examine a putative NR4A2-
CREB interaction.  
 
NR4A2 protein was detected in the cells overexpressing pEGFP-NR4A2, confirming 
the transfection (figure 3.9). In the MKN45 cells no bands were detected using 
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antibodies targeting β-catenin or CREB, suggesting that CREB and β-catenin do not 
directly interact with NR4A2. We anticipated that the binding partners might change 
after gastrin stimulation, expecting post-translational modifications to occur and new 
interactions to be formed, however, no detection of β-catenin was found in either 
untreated or cells treated with gastrin. Notably, TCF4 was detected in both the control 
and the cells expressing pEGFP-NR4A2, indicating that the TCF4 most likely 
interacts with the GFP-tag or the magnetic beads.  
 
 
Figure 3.9. NR4A2 does not interact with TCF4, β-catenin or CREB in MKN45 cells. The cells 
were transfected with pEGFP-NR4A2 or pEGFP and treated with gastrin (10 nM). Cell extracts were 
immunoprecipitated and immunoblotted with the indicated antibodies. Total extracts (input) and AGS-
GR cells transiently transfected with pEGFP-NR4A2 was used as control. The data represents one of 
two independent experiments. 
 
The HEK293 cell line is frequently used when working with recombinant proteins 
[70]. Kitagawa et al. [71] reported NR4A2 to bind to β-catenin. In the HEK293 cells 
no bands were detected using β-catenin and CREB antibodies (figure 3.10), which 
indicates that neither β-catenin nor CREB interacts with NR4A2 in these cells. This is 
in accordance with the findings of Rajalin & Aarnisalo that did not detect a direct 
interaction with β-catenin and NR4A2 in the U2-OS cells [72]. Notably, it is 
important to note that the paper from Kitawaga et al. was retracted from Molecular 
and Cellular Biology [71]. 
 
IB: CREB!
IB: TCF4!
IB: β-catenin!
IB: NR4A2!
IP: αGFP!
Gastrin (hours)         0            2          4          0           2           4            0           0            8 !
pE
GF
P !
pE
GF
P- 
NR
4A
2 !
AGS-GR!
!93 kDa!
!43 kDa!
!92 kDa!
!79 kDa!
pE
GF
P- 
NR
4A
2 !
pE
GF
P !
Input!
	  	  
 38	  
 
Figure 3.10. NR4A2 does not interact with β-catenin or CREB in HEK293 cells. The cells were 
transfected with pEGFP-NR4A2 or pEGFP. Cell extracts were immunoprecipitated and immunoblotted 
with the indicated antibodies. Total extract (input) and AGS-GR transiently transfected with pEGFP-
NR4A2 cell lysate was used as control. The data represent one of two independent experiments. 
 
3.5 NR4A2 binding proteins detected by Mass Spectrometry 
To get an overview of all the protein-protein interactions with NR4A2 in both the cell 
lines, we decided to use a Mass Spectrometry-based approach on the IP samples. 
Initially, to verify the transfection of the samples, 200 µg of the IP samples were 
immunoblotted for anti-GFP and anti-NR4A2 (figure 3.11).  
 
 
Figure 3.11. Expression of EGFP-NR4A2 or EGFP. The cells were transfected with pEGFP-NR4A2 
and pEGFP. Cell extracts were immunoprecipitated and immunoblotted with the indicated antibodies.  
 
The MS results were analysed with the two algorithms, Sequest and Mascot, which 
scores peptides and peptide fragments, respectively. The total number of proteins 
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detected by MS in both the cell lines was 453. The samples were normalised and the 
log2 ratio of the samples were calculated. By using this approach we detected many 
new potential binding partners of NR4A2. The detection cut-off in IPA was decided 
to be log2 ratio ≥ 0.58, meaning that the proteins that bind to both EGFP-NR4A2 and 
EGFP are still included in the analysis if they bind 1.5 more to EGFP-NR4A2 
compared to EGFP. The complete lists of potential interacting partners of NR4A2 in 
both MKN45 and HEK293 are shown in Appendix 4. The results are summarized in 
the Venn diagram (figure 3.12). 
 
 
Figure 3.12. Venn diagram of the proteins detected by Mascot and Sequest. 
 
Ingenuity Pathway Analysis (IPA) was used as a tool for annotations and 
visualization of the data. The proteins identified had a range of different biological 
functions including regulators of transcription, phosphatases, kinases and enzymes. 
Networks and functional analyses were generated for each sample to determine if the 
proteins in the dataset were interacting with each other and whether there were 
overlap between the datasets and well-known molecular functions and diseases. The 
highest scoring network for each of the samples is presented, whereas the remaining 
networks are presented in appendix 5. The 3 most interesting of the top 5 molecular 
functions and diseases are represented in the tables. 
 
3.5.1 IPA analyses of the proteins detected in MKN45 cells  
The whole dataset was uploaded on to Ingenuity Pathway Analysis to generate 
protein-protein interaction network. Of the proteins detected using the Sequest 
algorithm, 16 proteins scored a log2 ratio ≥ 0.58. Of this 3 statistically significant 
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networks were generated. The highest scoring network had a score of 26, meaning 
that there is a 1 in 1026 chance of this network to occur by random chance. The 
networks consisted of 35 proteins, whereas 10 of the proteins were found in the 
dataset. The network was annotated to functions like i) cellular development, ii) 
connective tissue development and function and iii) cellular assembly and 
organization (figure 3.13). A functional analysis in IPA was further performed to 
uncover proteins in the dataset that overlap with well-established molecular functions 
and diseases, presented in table 3.1. As expected the analysis showed interactions 
with proteins regulated in tumorigenesis and gastrointestinal disease.  
 
 
Figure 3.13. Network of proteins detected by the Sequest algorithm in MKN45 cells. The network 
consists of 35 molecules and is annotated to cellular development, connective tissue development and 
function and cellular assembly and organization. Red color indicates positive values, gray color 
represents proteins that did not meet the cut-off value, and white is proteins from IPA knowledge 
database associated with proteins in the network. Solid and dashed lines indicate direct and indirect 
interactions between proteins, respectively.  
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Table 3.1. IPA analysis of proteins found by the Sequest algorithm in MKN45 cells. Biological 
functions and diseases associated with the proteins found to bind to NR4A2.  
 Proteins P-value 
Molecular and cellular functions 
Cellular function and 
maintenance 
GPC3, LRP1B, UBR4, ZNF423, LGR4 6.78E-04-3.21E-02 
Cellular development  GPC3, LGR4, ZNF423, MAST2, TDRD6, HDAC9 1.36E-03-4.65E-02 
Cell growth and 
proliferation 
GPC3, LGR4, ZNF423 1.36E-03-3.83E-02 
Disease and disorders	  
Cancer DNAH17, LGR4, RPL4, ZNF423, GEMIN4, 
LRP1B, TDRD6, GPC3, MAST2, UBR4, HDAC9, 
PVRIG, USP24 
3.82E-05-4.26E-02 
Gastrointestinal Disease  DNAH17, LRP1B, UBR4, GEMIN4, MAST2, 
USP24, GPC3, RPL4, LGR4, TDRD6 
6.78E-04-3.27E-02 
Neurological disease HDAC9, ZNF423 6.78E-04-4.84E-02 
 
When analysing the proteomic data by the Mascot algorithm, 11 proteins above the 
threshold were detected. Mascot and Sequest detected no common proteins with log2 
ratio ≥ 0.58. According to PROMEC, typically 60-80% overlap in the results from 
Mascot and Sequest are found when analysing cell extract, however, MS performed 
on IP extracts gives more variations in the identification of proteins. The protein 
network made of the proteins detected by Mascot contained 10 of the 11 proteins, and 
was annotated to i) tissue morphology, ii) cell morphology, and iii) cellular assembly 
and organization (score of 30) (figure 3.14). Notably, both the algorithms annotated 
many of the same molecular functions and diseases (table 3.2), indicating that both 
the algorithms should be valuated to the same degree. 
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Figure 3.14. Network of proteins detected by the Mascot algorithm in MKN45 cells. The network 
consists of 35 molecules and is annotated to tissue morphology, cell morphology, and cellular assembly 
and organization. Red color indicates positive values, gray color represents proteins that did not meet 
the cut-off value, and white is proteins from IPA knowledge base associated with proteins in the 
network. Solid and dashed lines indicate direct and indirect interactions between proteins, respectively. 
 
Table 3.2. IPA analysis of proteins found by the Mascot algorithm in MKN45. Biological 
functions and diseases overlapping with the proteins found to bind to NR4A2.  
 Proteins P-value 
Molecular and cellular functions 
Cellular function and 
maintenance 
ANK3, MYO6, PPP1R12A, STK11, CHRM3 4.38E-04-3.28E-02 
Cell cycle  STK11, CHMR3, PPP1R12A  5.74E-04-3.22E-02 
Cellular assembly and 
organization 
ANK3, MYO6, PPP1R12A, STK11, CHMR3 5.74E-04-3.26E-02 
Disease and disorders	  
Cancer ANK3, CHMR3, STK11, MYO6, PPP1R12A, 
DHX16, TRIM58, RPL6 
5.74E-03-1.37E-02 
Developmental disorders ANK3, CHRM3, STK11, MYO6 5.74E-03-2.39E-02 
Gastrointestinal Disease  ANK3, CHRM3, STK11, MYO6, PPP1R12A, 
DHX16, TRIM58 
5.74E-03-4.39E-02 
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3.5.2 IPA analyses of the proteins detected in gastrin treated MKN45 cells  
We have recently shown that gastrin influences the NR4A2 nucleus/cytosol shuttling 
in AGS-GR cells [51]. We hypothesized that gastrin may induce similar effects in 
MKN45, and the cells were therefore treated with gastrin (30 minutes) before the MS 
analysis. Stimulated MKN45 cells overexpressing EGFP-NR4A2 were compared to 
stimulated controls overexpressing EGFP. The network analysis of the 4 proteins 
detected by the Sequest algorithm were annotated to functions associated with i) 
cellular function and maintenance, ii) molecular transport, and iii) cellular assembly 
and organization (score of 12) (figure 3.15). The functional analysis is shown in table 
3.3.  
 
Figure 3.15. Network of proteins detected by the Sequest algorithm in MKN45 cells treated with 
gastrin. The network consists of 35 molecules and is annotated to cellular function and maintenance, 
molecular transport, and cellular assembly and organization. Red color indicates positive values, gray 
color represents proteins that did not meet the cut-off value, and white is proteins from IPA knowledge 
base associated with proteins in the network. Solid and dashed lines indicate direct and indirect 
interactions between proteins, respectively. 
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Table 3.3. IPA analysis of proteins found by the Sequest algorithm in MKN45 cells treated with 
gastrin. Biological functions and diseases overlapping with the proteins found to bind to NR4A2. 
 Proteins P-value 
Molecular and cellular functions  
Cellular assembly and organization  SYTL1 2.09E-04-1.67E-03 
Cellular function and maintenance SYTL1 2.09E-04-2.22E-02 
Molecular transport  SYTL1, PKD2L1 2.09E-04-2.34E-03 
Disease and disorders  
Endocrine System disorders SYTL1 1.67E-03-1.67E-03 
Gastrointestinal disorders SYTL1 1.67E-03-1.67E-03 
 
The Mascot algorithm detected 7 proteins. These proteins were all found in the 
network associated with i) hereditary disorder, ii) neurological disease and iii) 
psychological disorders (score of 21) (figure 3.16). The molecular functions and 
diseases associated with the proteins detected are listed in table 3.4. After treatment 
with gastrin, different protein interaction was detected. However, one protein was 
detected by Mascot in both cell lines, 60S ribosomal protein L6 (RPL6), which has 
been shown to be higher expressed in gastric cancer tissue compared to normal gastric 
mucosa [73]. In the present study, the overall number of proteins detected in the 
stimulated cells was lower compared to the untreated cells. This suggests that the 
results should be interpreted critically and the experimental setup should be repeated.  
	  	  
 45	  
 
Figure 3.16. Network of proteins detected by the Mascot algorithm in MKN45 cells treated with 
gastrin. The network consists of 35 molecules and is annotated to hereditary disorder, neurological 
disease and psychological disorders. Red color indicates positive values, gray color represents proteins 
that did not meet the cut-off value, and white is proteins from IPA knowledge base associated with 
proteins in the network. Solid and dashed lines indicate direct and indirect interactions between 
proteins, respectively. 
 
 
Table 3.4. IPA analysis of proteins found by the Mascot algorithm in MKN45 cells treated with 
gastrin. Biological functions and diseases overlapping with the proteins found to bind to NR4A2. 
 Proteins P-value 
Molecular and cellular functions 
Lipid metabolism  MX1, PLA2G4B 3.13E-04-1.25E-03 
Cell cycle PPP1R12C 3.13E-03-3.13E-03 
Cell death and survival MX1 4.38E-03-4.38E-03 
Disease and disorders	  
Infectious disease MX1 3.13E-04-3.09E-02 
Cancer MX1, RPL13, RPL6 6.53E-04-2.39E-02 
Inflammatory disease MX1 1.22E-02-4.82E-02 
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3.5.3. IPA analysis of the proteins detected in HEK293 
Overall, more proteins were detected in HEK293 cells compared to the MKN45 cells, 
however the network gave very similar results for those detected in MKN45 cells. 31 
proteins were detected in the HEK293 cells using the Sequest algorithm. Three 
statistically significant networks were generated. The highest scoring network 
contained 27 proteins associated with i) cellular assembly and organization, ii) 
cellular function and maintenance, and iii) developmental disorders (score 82) (figure 
3.17). The molecular functions and diseases associated with the proteins detected by 
Sequest are listed in table 3.5. Proteins with similar functions as those found in 
MKN45 are detected in the HEK293 cells as well.  
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Figure 3.17. Network of proteins detected by the Sequest algorithm in HEK293 cells. The network 
consists of 35 molecules and is annotated to cellular assembly and organization, cellular function and 
maintenance, and developmental disorders. Red color indicates positive values, gray color represents 
proteins that did not meet the cut-off value, and white is proteins from IPA knowledge base associated 
with proteins in the network. Solid and dashed lines indicate direct and indirect interactions between 
proteins, respectively.  
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Table 3.5. IPA analysis of proteins found by the Sequest algorithm in HEK293 cells. Biological 
functions and diseases overlapping with the proteins found to bind to NR4A2. 
 Proteins P-value 
Molecular and cellular functions 
Cell assembly and 
organization 
CORO1A, CORO1C, DBN1, JUP, SPTAN1, 
TLN1, KIF2C, DBNL, SMC1A 
7.00E-06-4.44E-02 
Cellular function and 
maintenance 
CORO1A, CORO1C, DBN1, JUP, SPTAN1, 
TLN1, KIF2C, SMC1A, KHDRBS1, LRP5 
7.00E-06-3.81E-02 
Cell-to-cell signalling and 
interactions 
JUP, TLN1, DBN1, SERBP1, LRP5, CORO1A 1.62E-03-3.66E-02 
Disease and disorders	  
Cardiovascular disease JUP, LRP5 1.62E-03-4.44E-02 
Developmental disorder JUP, LRP5, GNE, GLUD1, SMC1A 1.62E-03-1.92E-02 
Gastrointestinal disease GLUD1 1.62E-03-1.62E-03 
 
37 proteins were detected in HEK293 cells by the Mascot algorithm and two networks 
were generated. The highest scoring network developed by IPA contains 23 of the 
proteins and was associated with i) cellular assembly and organization, ii) 
developmental disorder, and iii) hereditary disorder (score of 62) (figure 3.18). The 
molecular functions and diseases associated with the proteins detected by Mascot 
(table 3.6) are partly overlapping with Sequest. Both the algorithms detect three 
proteins in common, CORO1A, SMC1A and DBN1. CORO1A is a member of the 
WD-repeat actin binding proteins that have been shown to regulate cytoskeleton and 
membrane trafficking [74]. Mutation in SMC1A are responsible for the genetic 
disorder Cornelia de Lange syndrome and has been speculated to play a role in 
carcinogenesis [75]. DBN1 is suggested to be involve in colorectal cancer metastasis 
[76].  
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Figure 3.18. Network of proteins detected by the Mascot algorithm in HEK293 cells. The network 
consists of 35 molecules and is annotated to cellular assembly and organization, developmental 
disorder, and hereditary disorder. Red color indicates positive values, gray color represents proteins 
that did not meet the cut-off value, and white is proteins from IPA knowledge base associated with 
proteins in the network. Solid and dashed lines indicate direct and indirect interactions between 
proteins, respectively. 
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Table 3.6. IPA analysis of proteins found by the Mascot algorithm in HEK293 cells. Biological 
functions and diseases overlapping with the proteins found to bind to NR4A2. 
 Proteins P-value 
Molecular and cellular functions 
RNA post-transcriptional 
modifications 
DDX17, DDX54, PTBP1, RBM17, RBMX, RPS16, 
SF3A1 
1.55E-06-2.48E-02 
Cell assembly and 
organization 
ANLN, CORO1A, DBN1, DSP, DST, LIG3, 
MPRIP, MSH6, NIPBL, PTBP1, SMC1A, TIMM50, 
VASP 
2.17E-05-4.35E-02 
Cell death and survival  ANLN, CCT2, CORO1A, DDX17, DSP, DST, 
HSPD1, LIG3, MPRIP, MSH6, PA2G4, PPP2R3A, 
RBM17, RPS3, SF3A1, SMC1A, TIMM50, 
TRIM28, UBA1, VASP 
5.10E-04-4.90E-02 
Disease and disorders	  
Developmental disorder DST, ALDH18A1, DSP, UBA1, VASP, SMC1A, 
NIPBL 
3.61E-05-5.78E-03 
Hereditary disorder NIPBL, SMC1A, DSP, ALDH18A1, MSH6, DST, 
UBA1, HSPD1 
3.61E-05-1.91E-02 
Cancer COPE, CORO2A, DBN1, DDX17, DSP, DST, 
EPPK1, HSPD1, LIG3, MPRIP, MSH6, MYO1D, 
NIPBL, PTBP1, RBMX, RPL6, RPS3, RPS16, 
RPS4X, SF3A1, SMC1A, UBA1, VASP 
6.47E-05-4.02E-02 
 
The content source of IPA, Ingenuity Knowledge Base, includes manually curated 
data from published literature, internally curated knowledge and manually reviewed 
content from databases and other sources (http://ingenuity.com). The networks had 
different amount of proteins, and a high network score is seen with a higher number 
of proteins. A score ≥ 1.3 (p-value ≤	 0.05) indicates a 95% confidence that the 
network is not generated by random. The scores of the networks represented varied 
from 12-82 and were considered significant. 
 
The log2 ratios alone do not identify the proteins as interaction partners, therefor the 
protein interactions detected need to be further confirmed and validated through in 
vitro experiments to identify true interaction partners of NR4A2. To verify the 
interaction between NR4A2 and Serine/threonine-protein kinase STK11 (STK11), the 
IP lysate made from the MKN45 cells were analysed by Western blot with antibodies 
targeting STK11. The result (figure 3.19) shows that STK11 binds to both EGFP-
NR4A2 and EGFP, indicating that further optimization is needed. Another approach 
to validate the interaction between NR4A2 and STK11 may be by confocal imaging, 
to determine co-localization.   
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Figure 3.19. STK11 bind both EGFP-NR4A2 and EGFP in MKN45 cells. The cells were 
transfected with pEGFP-NR4A2 or pEGFP and treated with gastrin (10 nM). Cell extracts were 
immunoprecipitated and immunoblotted with the antibody targeting STK11. Total extracts (input) was 
used as control. 
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5.0 Discussion  
The role of gastrin in gastric adenocarcinoma has been debated for many years, and it 
still remains unclear. Knowledge of gastrin-mediated molecular mechanisms and 
target genes can contribute to a better understanding of its role in carcinogenesis, as 
well as its normal function. In the present study, we have shown that gastrin induces 
the expression of NR4A2 in the gastric adenocarcinoma cell line MKN45. NR4A2 
has been described as a putative prognostic marker in gastric cancer. To further 
elucidate its role, NR4A2 was overexpressed in the MKN45 and HEK293 cells. No 
interactions were observed between NR4A2 and the proteins initially hypothesized to 
bind to NR4A2. However, Mass Spectrometry (MS) in combination with 
Immunoprecipitation (IP) identified several potential binding partners. This thesis 
provides an overview of putative interactions partners of NR4A2 that may be 
important in gastric cancer.  
 
The NR4A family of transcription factors have been shown to affect the cellular 
responses and the subcellular localization seems to be important for their function in 
regulation of cell survival [46, 77]. Generally, it appears that in the nucleus the NR4A 
receptors regulate transcription implicated in differentiation and survival [78, 79]. A 
cytoplasmic localization of NR4A2 has been proposed as a prognostic factor in 
bladder cancer and was associated with lower survival rate [30]. The proposed 
mechanism comprised the translocation of NR4A2 to the cytoplasm, which allows 
cells to invade and metastasize because of the termination of its role in transcription 
[30]. Pro-apoptotic roles have been shown for NR4A1 and NR4A3, which include 
translocation to mitochondria, interaction with Bcl-2 proteins and promotion of cell 
death [80, 81]. This reveals an additional mechanism other than regulation of 
transcription.  
 
Generally, by use of MS in combination with IP several proteins can be identified in a 
single experiment, and typically 70-600 proteins are identified [82]. For quantitative 
data analysis of the MS raw-data, both Mascot and Sequest algorithms were used to 
identify protein-protein interactions in this study. The networks revealed very similar 
cellular processes for the two cell lines. In general, more proteins were detected in 
HEK293 cells compared to MKN45 cells. This might reflect the capability of 
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HEK293 cells to generate functional mature proteins [70]. Cancer cells express a 
different set of proteins compared to normal cells, especially alteration in cell-surface 
proteins and the nuclear proteomes [83]. Taken together, we did not expect to find all 
of the same proteins in the two cell lines. Further, our proteomic analyses need to be 
repeated to examine the reproducibility of the binding partners, and the proteins 
detected must be verified by other in vitro experiments. 
 
In general, the annotations of the protein-protein networks were broad and the 
functional analysis gave a myriad of functions. This suggests that NR4A2 has an 
active role in many different biological processes. These include associating with 
proteins in the cytoskeleton, in cell signalling cascades, as well as proteins regulating 
transcription, post-transcriptional modifications, translation and DNA repair. The role 
of NR4A2 in regulation of these processes is poorly described up to date. The 
networks generated in this thesis should be regarded as a starting point for further 
investigation both to put forward hypotheses and to identify important cellular 
processes. The NR4A receptors have been shown to play essential roles in 
development and cellular homeostasis [28]. Our annotated networks included cellular 
development, cell morphology, cellular assembly and organization and are highly 
reliable since these biological functions are confirmed for NR4A2 in other studies. 
NR4A2 has been identified as an important factor in maintenance and development of 
the dopaminergic neurones in the brain [84], and mice lacking the NR4A2 expression 
die shortly after birth [85]. Mutations in NR4A2 are associated with 
neurodegenerative disorders like Parkinson [86, 87] and may be involved in the 
pathogenesis of schizophrenia [88, 89].  
 
The proteomic results included proteins already published to bind to NR4A2 e.g. 
splicing factor, proline- and glutamine-rich (SFPQ) [90] and Poly [ADP-ribose] 
polymerase 1 (PARP-1) [91, 92]. However, these proteins had a low abundance in our 
experiment and did not make the decided cut-off of log2 ratio ≥ 0.58. PARP-1 has 
been shown to bind NR4A2 upon exposure to DNA damage, and translocate to the 
double-strand break foci where NR4A2 promotes double-strand break repair [92]. 
PARP-1 is also essential for NR4A2 recruitment to UV induced foci where it is 
involved in nucleotide excision repair [91]. Collectively, these studies may suggest a 
cell survival role for NR4A2. Interestingly, our results showed that the DNA 
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mismatch repair protein msh6 (MSH6) could bind to NR4A2. Further studies should 
be conducted to investigate whether NR4A2 binds to other DNA repair proteins and 
by this play a role in DNA repair.  
 
Plasminogen activator inhibitor 1 RNA-binding protein (SERBP1) is a binding 
protein of plasminogen activator inhibitor 1 (PAI-1) mRNA and regulates the mRNA 
stability [93]. Our data suggest interactions of NR4A2 and SERBP1, which may 
indicate that NR4A2 can be part of the SERBP1 regulation complex. PAI-1 is a part 
of the urokinase plasminogen activator (uPA) system that is involved in degradation 
of basement membrane and the extracellular matrix that leads to cell invasion and 
metastasis [94]. Expression of PAI-1 and uPA is associated with poor prognosis in 
various cancers, including gastric cancer [95-97]. Previous studies in our research 
group have shown that gastrin induces the protein expression of PAI-1. Knock-down 
of PAI-1 increased gastrin mediated invasion and migration in the AGS-GR cells, 
suggesting that PAI-1 plays an important role in restraining the effect of gastrin on 
cell motility [97]. Notably, when NR4A2 is knocked-down in the AGS-GR cells an 
increase in the migration was observed [51], thus we speculate that NR4A2 may 
participate in stabilizing of PAI-1. The mechanisms controlling the expression and the 
role of PAI-1 in the gastric cancer is not fully understood, and further studies to 
characterize the function of NR4A2 and PAI-1 in gastric cancer would be highly 
interesting.  
 
The Wnt-signalling pathway is central in the regulation of cell proliferation, migration 
and differentiation, and is often deregulated in gastric cancer [64, 65]. In absence of 
Wnt β catenin is regulated by a complex of Adenomatous polyposis coli (APC), Axin 
and GSK3β. Binding of Wnt-proteins to its receptor Frizzled and co-receptors low-
density lipoprotein receptor-related protein 5/6 (LPR 5/6), subsequently blocks the 
phosphorylation and degradation of β-catenin [66, 98]. The results from our IP 
experiment showed that NR4A2 did not bind β–catenin in either MKN45 (figure 3.9) 
or HEK293 cells (figure 3.10). However, cross-talk between all NR4A receptors and 
β–catenin signalling pathway has been shown in the osteoblastic cell line U2-OS [72].  
 
Several proteins in the Wnt-signalling pathway were detected to bind to NR4A2 by 
the proteomic approach. Microtubule-actin cross-linking factor 1 (MACF1) is a 
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positive regulator of the Wnt-signalling pathway, known to interact with Axin and 
involves the translocation of the Axin-complex to the LRP 5/6 at the cell membrane 
resulting in β–catenin accumulation [99]. A recent study found that 4/30 diffuse-type 
gastric carcinomas possess mutations in the MACF1 gene [100]. Two receptors in the 
Wnt-signalling pathway were also detected, Frizzled-10 (FZD10) and Leucine-rich 
repeat-containing G-protein coupled receptor 4 (LGR4) [101, 102], and both proteins 
have been reported to be up-regulated in gastric intestinal cancer [102, 103]. 
Altogether these findings indicate that NR4A2 may modulate the Wnt-signalling 
pathway in at least two ways, either by directly binding the receptors or by regulating 
the translocation of the β-catenin complex to the receptors. Zagani et al. [49] has 
shown that blockage of NR4A2 and simultaneously inhibition of the Wnt/β-catenin 
signalling reduced tumor growth in vivo [49]. Interactions between NR4A2 and 
proteins in the Wnt-signalling pathway should be further explored. 
 
NR4A2 has been shown to promote cell survival by interacting with p53 and repress 
the induction of pro-apoptotic genes [104]. Noteworthy, p53 is an important regulator 
of autophagy [105, 106]. Bouzas-Rodriguez et al. [107] have shown that NR4A1 can 
promote autophagy-mediated cell death. A fraction of the NR4A1 receptors were 
located in the cytoplasm, and shown to interact with p53. The mechanisms to promote 
cell death may involve protein-protein interaction as well as regulation of gene-
expression of pro-autophagy genes. Interestingly, although this study refer to NR4A1, 
they did not rule out the possibility that NR4A2 could play a role in autophagy [107].  
 
Serine/threonine-protein kinase STK11 (STK11) is often mutated in cancer [108, 
109]. Germ line mutations in STK11 are responsible for Peutz-Jeghers syndrome and 
these patients have an increased risk of developing cancer, especially gastrointestinal 
cancers [109]. STK11 phosphorylates and activates at least 14 protein kinases and 
regulates cellular processes like cell division, cell growth and energy metabolism 
[110]. STK11 phosphorylates the AMP-activated protein kinase (AMPK) that 
regulates glucose and lipid metabolism in response to changes in intracellular energy 
level and nutrients [111]. The group has preliminary data showing that gastrin 
phosphorylates STK11-AMPK-ULK pathway and initiates autophagy, which may in 
part regulate the anti-apoptotic effect of gastrin (manuscript in preparation). The 
interaction between the NR4A receptors and STK11 is not fully understood. NR4A1 
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has been shown to sequester STK11 in the nucleus and hinder its cytoplasmic 
translocation and subsequently phosphorylation of AMPK [112]. Taken together, 
STK11 is found to be an interesting candidate protein for future work to generate new 
hypothesis regarding the role of both NR4A2 and STK11 in gastric cancer.  
 
Some considerations regarding the experimental setup in this study need to be 
discussed. The preliminary results (figure 3.19) showed that the interaction between 
NR4A2 and STK11 could not be confirmed by Western blot, which underscore that 
further experiments and optimization is needed. For IP; the stringency of the washing 
buffer is essential to obtain a pure sample of the antigen and the antigen-binding 
partners. In the MS data, STK11 was detected only in the EGFP-NR4A2 sample of 
untreated MKN45 cells, however by the Western blot we detected binding of both 
EGFP-NR4A2 and EGFP. To investigate the interaction between NR4A2 and STK11, 
and optimize the IP and further, a dilution series of different concentrations of KCl in 
the washing buffer could be performed. If the protein dissociates at a lower salt 
concentration from EGFP compared to EGFP-NR4A2, this would reveal a stronger 
binding between NR4A2 and STK11, which confirms their interaction. The non-
specific band at 50-55 kDa is most likely the heavy chain of IgG. The antibody used 
to immunoprecipitate was rabbit, thus it would be better to use an antibody from a 
different species when blotting for STK11.  
 
Protein-protein interactions are essential for almost every process in a living cell. 
Multi-protein complexes are involved in the regulation of many biological processes, 
and the majority of proteins are dependent on protein interactions for proper activity. 
The protein-protein interactions are highly dynamic and regulated by particular 
signals and the specific status of the cell [113]. In this study, we have identified 
putative protein-protein interactions of NR4A2, which uncover the versatile role of 
NR4A2. The study has provided ideas about the molecular mechanisms where 
NR4A2 may play a dual role, which may determine the cellular phenotype. Further 
investigation is needed to unravel whether gastrin regulates NR4A2 dependent 
cellular functions. As NR4A2 has been suggested to be a prognostic marker in gastric 
cancer. A better understanding of the molecular mechanisms involving NR4A2 is 
important to further uncover its role in cancer therapy.  
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Appendix 
Appendix 1 
The EGFP-NR4A2 plasmid, shown in figure A1.1.  
 
Figure A1.1. EGFP-NR4A2 plasmid.  
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Appendix 2  
A melt curve analysis was performed, and shown in figure A2.1.  
 
Figure A2.1. The melt curve of the PCR products. The melt curve shows the melt curve of β-actin in 
pink, and NR4A2 in green. The data represent one of two biological experiments. 
  
	  	  
 67	  
Appendix 3 
HEK293 and MKN45 were seeded in 96-well plates and cultivated for 24 hours. The 
cells were then transfected with 0.1µg plasmid and 0.5 µl Metafectene PRO/ well. The 
MTT analysis was performed 48 hours after transfection.  
 
No statistical significance (p-value ≤0.05) between the transfected cells was identified 
using a two-tailed independent Student´s t-test. 
 
 
Figure A3.1. Viability assay of transfected cells. HEK293 cells and MKN45 (A and B, respectively) 
were transfected with the plasmids indicated. Transfection of the cells does not affect the viability of 
the cells significantly (p-value ≤ 0.05). The data shown is mean ± SD. 
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Appendix 4 
Ingenuity Pathway Analysis was used to generate networks of the proteins detected 
after Mass Spectrometry of the immunoprecipitated samples. The detection cut-off in 
IPA was decided to be log2 ratio ≥ 0.58. The complete lists of potential interacting 
partners of NR4A2 in untreated MKN45 cells (table A4.1), gastrin (30 minutes) 
treated cells (table A4.2) and HEK293 (table A4.3) are presented. 
 
Table A4.1. The proteins detected in US MKN45 cells  
 
Mascot Gene symbol Log2 value 
Myosin-VI (Unconventional myosin VI) MYO6 6,320 
Ankyrin-3 ANK3 5,515 
Tripartite motif-containing protein 58 TRIM58 5,424 
Serine/threonine-protein kinase STK11 STK11 5,319 
Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX16 DHX16 5,065 
Protein phosphatase 1 regulatory subunit 12A PPP1R12A 4,971 
Polypyrimidine tract-binding protein 3 ROD1 4,866 
60S ribosomal protein L6 RPL6 4,832 
Polyadenylate-binding protein 4 PABPC4 4,612 
PRAME family member 9 PRAMEF9 4,526 
Muscarinic acetylcholine receptor M3 CHRM3 4,525 
Sequest Gene symbol Log2 value 
Isoform 5 of E3 ubiquitin-protein ligase UBR4 1,784 
Tetratricopeptide repeat protein 23 (fragment) TTC23 1,722 
Isoform 2 of EF-hand calcium-binding domain-containing protein 4A EFCAB4A 1,642 
Low-density lipoprotein receptor-related protein 1B (fragment) LRP1B 1,611 
Transmembrane protein PVRIG PVRIG 1,597 
60S ribosomal protein L4 (Fragment) RPL4 1,547 
Isoform 2 of Tudor domain-containing protein 6 TDRD6 1,540 
Ubiquitin carboxyl-terminal hydrolase USP24 1,472 
Isoform 4 of Dynein heavy chain 17, axonemal DNAH17 1,186 
Nuclear pore complex-interacting protein family member A2 NPIPA2 1,163 
Zinc finger protein 423 ZNF423 1,129 
Microtubule-associated serine/threonine-protein kinase 2 MAST2 1,077 
Secreted glypican-3 (Fragment) GPC3 0,884 
Gem-associated protein 4 GEMIN4 0,751 
Isoform 2 of Leucine-rich repeat-containing G-protein coupled receptor 4 LGR4 0,720 
Isoform 11 of Histone deacetylase 9 HDAC9 0,687 
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Table A4.2. The proteins detected in MKN45 cells stimulated with gastrin (10 nM) for 30 minutes 
  
Mascot Gene symbol Log2 value 
Protein phosphatase 1 regulatory subunit 12C PPP1R12C 5,478 
Cytosolic phospholipase A2 beta  PLA2G4B 5,310 
60S ribosomal protein L6 RPL6 5,210 
Exosome complex component MTR3  EXOSC6 5,154 
Interferon-induced GTP-binding protein Mx1  MX1 4,924 
60S ribosomal protein L13  RPL13 4,579 
Frizzled-10  FZD10 4,539 
Sequest Gene symbol Log2 value 
Isoform 2 of 26S proteasome non-ATPase regulatory subunit 11  PSMD11 2,226 
Synaptotagmin-like protein 1  SYTL1 1,690 
Polycystic kidney disease 2-like 1 protein (Fragment)  PKD2L1 0,714 
N6-adenosine-methyltransferase 70 kDa subunit METTL3 0,687 
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Table A4.3. The proteins detected in HEK293 cells  
 
Mascot Gene symbol Log2 value 
Actin-binding protein anillin ANLN 5,808 
Multiple myeloma tumor-associated protein 2  MMTAG2 5,523 
Drebrin  DBN1 5,463 
40S ribosomal protein S4, X isoform  RPS4X 5,454 
Glutamine-rich protein 1  QRICH1 5,440 
Coronin-1A  CORO1A 5,434 
Desmoplakin DSP 5,414 
Splicing factor 3 subunit 1  SF3A1 5,346 
Serine/threonine-protein phosphatase 2A regulatory subunit B'' subunit 
alpha  PPP2R3A 5,322 
Epiplakin EPPK1 5,302 
Proliferation-associated protein 2G4  PA2G4 5,224 
T-complex protein 1 subunit beta  CCT2 5,223 
40S ribosomal protein S3 RPS3 5,182 
Transcription intermediary factor 1-beta  TRIM28 5,179 
Dystonin DST 5,179 
RNA-binding motif protein, X chromosome  RBMX 5,085 
60S ribosomal protein L6  RPL6 5,070 
Coiled-coil domain-containing protein 124  CCDC124 5,067 
Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform PPP2CB 5,042 
60 kDa heat shock protein, mitochondrial  HSPD1 5,039 
Coatomer subunit epsilon  COPE 4,976 
Vasodilator-stimulated phosphoprotein  VASP 4,937 
DNA mismatch repair protein Msh6  MSH6 4,925 
40S ribosomal protein S16  RPS16 4,900 
ATP-dependent RNA helicase DDX54  DDX54 4,842 
Ubiquitin-activating enzyme E1  UBA1 4,822 
Unconventional myosin-Id  MYO1D 4,729 
Coronin-2A  CORO2A 4,631 
Probable ATP-dependent RNA helicase DDX17 DDX17 4,599 
Nipped-B-like protein  NIPBL 4,581 
Mitochondrial import inner membrane translocase subunit TIM50  TIMM50 4,489 
Splicing factor 45  RBM17 4,472 
Polypyrimidine tract-binding protein 1  PTBP1 4,449 
Delta 1-pyrroline-5-carboxylate synthase ALDH18A1 4,391 
Myosin phosphatase Rho-interacting protein  MPRIP 0,809 
Structural maintenance of chromosomes protein 1A  SMC1A 0,630 
DNA ligase 3  LIG3 0,615 
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Sequest Gene symbol Log2 value 
Plasminogen activator inhibitor 1 RNA-binding protein  SERBP1 2,844 
Zinc finger CCHC domain-containing protein 3  ZCCHC3 2,066 
Structural maintenance of chromosomes protein 1A SMC1A 1,717 
Drebrin-like protein  DBNL 1,658 
Coronin-1C  CORO1C 1,652 
Drebrin  DBN1 1,545 
Isoform 2 of Leucine zipper protein 1  LUZP1 1,462 
Nuclear pore membrane glycoprotein 210  NUP210 1,460 
OTU domain-containing protein 7A  OTUD7A 1,417 
Dynein heavy chain 10, axonemal  DNAH10 1,392 
Olfactory receptor 3A3  OR3A3 1,297 
Isoform 5 of Bifunctional UDP-N-acetylglucosamine 2-epimerase/ 
N-acetylmannosamine kinase  GNE 1,174 
Mediator of RNA polymerase II transcription subunit 24  MED24  1,122 
Spectrin alpha chain, non-erythrocytic 1  SPTAN1 1,108 
Junction plakoglobin  JUP 1,065 
Coronin-1A  CORO1A 1,062 
Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5  MACF1 0,956 
Putative ATP-dependent RNA helicase DHX57  DHX57 0,942 
POTE ankyrin domain family member E  POTEE 0,924 
CTTNBP2 N-terminal-like protein CTTNBP2NL 0,913 
Kinesin-like protein KIF2C (Fragment)  KIF2C 0,900 
Talin-1  TLN1 0,881 
Uridine diphosphate glucose pyrophosphatase  NUDT14  0,880 
ATP synthase subunit alpha, mitochondrial  ATP5A1 0,865 
Polyubiquitin-C  UBC 0,858 
Low-density lipoprotein receptor-related protein 5  LRP5 0,838 
T-complex protein 1 subunit gamma (Fragment)  CCT3 0,797 
Threonine--tRNA ligase, mitochondrial  TARS2 0,752 
KH domain-containing, RNA-binding, signal transduction-associated 
protein 1 KHDRBS1 0,700 
Glutamate dehydrogenase 1, mitochondrial  GLUD1 0,693 
Protein phosphatase 1 regulatory subunit 12C  PPP1R12C 0,669 
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Appendix 5.  
Ingenuity Pathway Analysis was used to generate networks of the proteins detected 
after Mass Spectrometry of the immunoprecipitated samples. The associated network 
functions of the protein of the networks not presented in the result-part of MKN45 
cells detected by Sequest (table A5.1), HEK293 cells detected by Sequest (table A5.2) 
and Mascot (table A5.3) are presented. 
 
 
Table A5.1. MKN45 cells untreated (Sequest) 
Associated network functions Number of proteins from the dataset Score 
RNA post-transcriptional modifications, cell cycle, cellular growth 
and proliferation 
4 9 
Cellular assembly and organization, cell cycle, cell death and 
survival 
1 3 
 
Table A5.2. HEK293 cells (Sequest) 
Associated network functions Number of proteins from the dataset Score 
Carbohydrate metabolism, Lipid metabolism, small molecule 
biochemistry 
2 3 
Hereditary disorder, respiratory disease, organismal injury and 
abnormalities 
1 2 
 
Table A5.3. HEK293 cells (Mascot) 
Associated network functions Number of proteins from the dataset Score 
Connective tissue disorders, dermatological diseases and conditions, 
developmental disorders 
14 33 
 
 
 
 
